Alto Neuroscience
ANRO | NYSE
$27.12
-$2.42 (-8.19%)
At close: Nov 16, 2026, 4:00 PM ET
$27.12
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 4:01 PM ET
Alto Neuroscience Company Profile
Company profile explainedCompany Profile
Alto Neuroscience, Inc. operates as a biopharmaceutical entity in the clinical stage, specializing in the creation of novel psychiatric medications. Its development pipeline includes ALTO-100, an investigational therapy targeting individuals affected by major depressive disorder (MDD) and post-traumatic stress disorder. Also in its portfolio is ALTO-300, a small molecule designed to function as both a melatonergic agonist and serotonergic antagonist, exhibiting antidepressant properties for MDD patients. For addressing the cognitive impairments linked with schizophrenia, Alto Neuroscience is advancing ALTO-101, an innovative small molecule phosphodiesterase 4 inhibitor. The company's therapeutic candidates further extend to ALTO-203, a pioneering small-molecule histamine H3 receptor inverse agonist intended for MDD patients experiencing heightened anhedonia, and ALTO-202, an orally available antagonist of the GluN2B subunit of the NMDA receptor, also under investigation for MDD. Beyond these individual drug candidates, the firm is engaged in developing novel drug combinations that demonstrate synergistic pharmacodynamic effects. Crucially, Alto Neuroscience leverages an advanced AI-enabled biomarker platform that synthesizes data concerning patients' brain activity and behavioral patterns. This platform's purpose is to accurately identify which individuals are most likely to respond positively to its cutting-edge product candidates. Alto Neuroscience, Inc., established in 2019, maintains its headquarters in Los Altos, California.
Key Executives
| Name | Position |
|---|---|
| Amit Etkin | Founder, CEO & Chairman of the Board |
| Michael C. Hanley | Chief Operating Officer |
| Adam Savitz | Chief Medical Officer |
| Dan Segal | Co-Founder & Strategic Advisor |
| Erin R. McQuade | General Counsel, Chief Administrative Officer & Corporate Secretary |
| Jessica Powell | Chief Development Officer |
| Nicholas C. Smith | CFO & President |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 30, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Oct 05, 2026 | 4 | Filing |
| Oct 01, 2026 | 4 | Filing |
| Aug 27, 2026 | 8-K | Current Report |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 12, 2026 | 10-Q | Quarterly Report |
| Aug 12, 2026 | 8-K | Current Report |
| Jul 27, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
Alto Neuroscience
| Country | United States |
| IPO Date | Feb 2, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 68 |
| CEO | Amit Etkin |
Contact Details
650 Castro Street Mountain View,
California 94041 United States
Stock Details
| Ticker Symbol | ANRO |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001999480 |
| CUSIP Number | 02157Q109 |
| ISIN Number | US02157Q1094 |
| SIC Code | 2834 |
Recent News
- 13 hours ago / zacks.comAlto Neuroscience, Inc. (ANRO) Upgraded to Buy: Here's What You Should Know
- 15 hours ago / zacks.comWall Street Analysts Predict a 29.38% Upside in Alto Neuroscience, Inc. (ANRO): Here's What You Should Know
- 2 months ago / businesswire.comAlto Neuroscience Announces Participation in Upcoming Investor Conferences
- 3 months ago / businesswire.comAlto Neuroscience Promotes Nick Smith to President and Chief Financial Officer
Add to Watchlist
Select watchlists to add or remove ANRO